CNM-Au8 Fails at Key RESCUE-ALS Trial Goals, But Trends ‘Encouraging’

CNM-Au8 Fails at Key RESCUE-ALS Trial Goals, But Trends ‘Encouraging’

311226

CNM-Au8 Fails at Key RESCUE-ALS Trial Goals, But Trends ‘Encouraging’

CNM-Au8, an investigational disease-modifying therapy for people with early amyotrophic lateral sclerosis (ALS), failed to prevent motor neurons loss and lung function decline relative to a placebo, according to top-line data from the RESCUE-ALS Phase 2 clinical trial. The trial, in other words, did not meet its primary and a key secondary goal after 36 weeks of treatment: higher Motor Unit Number Index (MUNIX) scores — which measure the number, function, and health of motor neurons…

You must be logged in to read/download the full post.